These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 22565090)
21. Cardiovascular adverse effects of antipsychotic drugs. Buckley NA; Sanders P Drug Saf; 2000 Sep; 23(3):215-28. PubMed ID: 11005704 [TBL] [Abstract][Full Text] [Related]
22. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. Meltzer HY; Davidson M; Glassman AH; Vieweg WV J Clin Psychiatry; 2002; 63 Suppl 9():25-9. PubMed ID: 12088173 [TBL] [Abstract][Full Text] [Related]
23. Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system. Kahl KG; Westhoff-Bleck M; Krüger THC Vascul Pharmacol; 2018 Jan; 100():20-25. PubMed ID: 28888918 [TBL] [Abstract][Full Text] [Related]
24. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. Jafari S; Fernandez-Enright F; Huang XF J Neurochem; 2012 Feb; 120(3):371-84. PubMed ID: 22103329 [TBL] [Abstract][Full Text] [Related]
25. [Prevention and treatment of somatic complications arising from the use of antipsychotics]. Cahn W; Ramlal D; Bruggeman R; de Haan L; Scheepers FE; van Soest MM; Assies J; Slooff CJ Tijdschr Psychiatr; 2008; 50(9):579-91. PubMed ID: 18785105 [TBL] [Abstract][Full Text] [Related]
26. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Gonçalves P; Araújo JR; Martel F Eur Neuropsychopharmacol; 2015 Jan; 25(1):1-16. PubMed ID: 25523882 [TBL] [Abstract][Full Text] [Related]
28. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. Devlin AM; Panagiotopoulos C Pharmacogenomics; 2015; 16(9):981-96. PubMed ID: 26107755 [TBL] [Abstract][Full Text] [Related]
29. Metabolic side effects of atypical antipsychotics in children: a literature review. Fedorowicz VJ; Fombonne E J Psychopharmacol; 2005 Sep; 19(5):533-50. PubMed ID: 16166191 [TBL] [Abstract][Full Text] [Related]
30. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Vitiello B; Correll C; van Zwieten-Boot B; Zuddas A; Parellada M; Arango C Eur Neuropsychopharmacol; 2009 Sep; 19(9):629-35. PubMed ID: 19467582 [TBL] [Abstract][Full Text] [Related]
31. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Coccurello R; Moles A Pharmacol Ther; 2010 Sep; 127(3):210-51. PubMed ID: 20493213 [TBL] [Abstract][Full Text] [Related]
32. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Maayan L; Correll CU J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172 [TBL] [Abstract][Full Text] [Related]
33. Medical and legal implications of side effects from neuroleptic drugs. A round-table discussion. Cancro R; Davis JM; Klawans H; Tancredi L J Clin Psychiatry; 1981 Feb; 42(2):78-82. PubMed ID: 6109720 [TBL] [Abstract][Full Text] [Related]
34. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Strange PG Pharmacol Rev; 2001 Mar; 53(1):119-33. PubMed ID: 11171942 [TBL] [Abstract][Full Text] [Related]
36. Attention to medical conditions during mental health clinic visits. Miller MJ Clin Schizophr Relat Psychoses; 2013 Oct; 7(3):149-56. PubMed ID: 23367501 [TBL] [Abstract][Full Text] [Related]
37. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. Correll CU J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766 [TBL] [Abstract][Full Text] [Related]